Antibodies and antibody-derived macromolecules have established themselves as the
mainstay in protein-based therapeutic molecules (biologics). Our knowledge of the structure …

During the past two decades we have seen a phenomenal evolution of bispecific antibodies
for therapeutic applications. The 'zoo'of bispecific antibodies is populated by many different …

Bispecific antibodies are on the cusp of coming of age as therapeutics more than half a
century after they were first described. Two bispecific antibodies, catumaxomab (Removab® …

Inhibition of the Wnt antagonist sclerostin increases bone mass in patients with osteoporosis
and in preclinical animal models. Here we show increased levels of the Wnt antagonist …

Highlights•Therapeutic Abs come from critical screenings of in vivo and in vitro
methods.•Bispecific Abs increase specificity and broaden the range of therapeutic …

The major challenge in the generation of bispecific IgG antibodies is enforcement of the
correct heavy and light chain association. The correct association of generic light chains can …

Monoclonal therapeutic antibodies have revolutionized the treatment of cancer and other
diseases. Fc engineering aims to enhance the effector functions or half-life of therapeutic …

ABSTRACT A bispecific antibody (bsAb) is able to bind two different targets or two distinct
epitopes on the same target. Broadly speaking, bsAbs can include any single molecule …

Bispecific antibodies have recently attracted intense interest. CrossMab technology was
described in 2011 as novel approach enabling correct antibody light-chain association with …

Therapeutic monoclonal antibodies have become molecules of choice to treat autoimmune
disorders, inflammatory diseases, and cancer. Moreover, bispecific/multispecific antibodies …